Stein Steven H sold $3.2M of INCY

Stein Steven H (CMO & Head of Late-Stage Dev.) sold 28,237 shares of INCYTE CORP (INCY) at $113.05 ($3.19M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Stein Steven H
Published Jul 16, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings; it does not introduce new company fundamentals.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure limits interpretive value.

03

What to watch

The filing does not disclose any change in company guidance, trial results, or business performance; traders should avoid extrapolating fundamentals from a single planned sale.

Relevance 5/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-07-16)

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by an officer (CMO and Head of Late-Stage Development).

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows officer Stein Steven H sold 28,237 shares at $113.05 on 2026-07-15 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine open-market sale by an officer, explicitly under a pre-arranged Rule 10b5-1 plan, with no new operational, financial, or regulatory information disclosed.

Market effects

Minimal; insider-sale disclosures rarely reset sector expectations without accompanying company-specific catalysts.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • INCY

    Incyte Corp, the subject of the Form 4 insider transaction.

  • Stein Steven H

    CMO and Head of Late-Stage Development who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INCYHighAI 8/10

Incyte Advances Pancreatic and Colorectal Cancer Drug Trials

Incyte Corp. (INCY) is advancing two cancer treatments, INCB161734 and INCA33890, into late-stage trials after early results showed promising responses in pancreatic and colorectal cancers. INCB161734, combined with chemotherapy, showed high response rates in pancreatic cancer, while INCA33890 demonstrated activity in colorectal cancer. The company plans Phase 3 trials with topline results expected in 2028 and 2029, respectively.

$INCYMed

Incyte wins Indian patent injunction just weeks before expiration

Incyte secured an interim injunction in India against Melody Healthcare regarding its ruxolitinib patent, just 11 weeks before the patent's expiration. The Delhi High Court ruled in favor of interim protection due to the patent's remaining validity and lack of competing commercial launch. According to the court, this ruling highlights the availability of interim protection against threatened infringement before a rival's commercial launch.

$INCYMedAI 8/10

Ruxolitinib Cream Well Tolerated in Children With AD

A phase 3 study found that ruxolitinib cream was well tolerated and maintained disease control in children aged 2-11 with mild to moderate atopic dermatitis (AD) over 44 weeks. The study, funded by Incyte Corporation, showed 79.5% of children on 0.75% strength and 72.3% on 1.5% had clear or almost clear skin at week 52. Common side effects included upper respiratory tract infection and neutropenia. The authors suggest ruxolitinib cream as a potential corticosteroid-free treatment option for AD.